Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
19 November, 2017 23:16 IST
Zydus receives approval from USFDA for Mesalamine suppositories
Source: IRIS | 11 Aug, 2017, 05.12PM
Comments  |  Post Comment

Zydus Cadila has received the tentative approval from the USFDA to market Mesalamine Suppositories for rectal use, 1000 mg.

Mesalamine is used to treat an inflammatory bowel disease, such as ulcerative colitis. It will be produced at the group's Topical plant at Ahmedabad.

The group now has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company gained Rs 17.55, or 3.77%, to settle at Rs 482.95. The total volume of shares traded was 401,757 at the BSE (Friday).





Cadila Healthcare Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
Tata Communications joins hands with The European Tour - 17-Nov-2017 10:27
Hinduja Ventures enters into agreements to hike stake in HLFL - 17-Nov-2017 10:23
Cipla receives final approval for generic Pulmicort Respules - 17-Nov-2017 10:16
Tata Power raises Rs 15 bn on private placement basis - 17-Nov-2017 10:09
Indian Navy signs contract with Tata Power for supply of PDDS - 17-Nov-2017 10:06
ICICI Bank, Paytm tie-up to offer short term instant digital credit - 17-Nov-2017 10:00
Wipro launches industry-specific solutions on SAP Leonardo - 17-Nov-2017 09:56
Infosys in collaboration with ATP launches Second Screen - 17-Nov-2017 09:52
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer